Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
OGEN

OGEN - Oragenics Inc Stock Price, Fair Value and News

$0.89-0.07 (-7.29%)
Market Closed

82/100

OGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

82/100

OGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

OGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OGEN Price Action

Last 7 days

-1.1%

Last 30 days

34.8%

Last 90 days

-2.2%

Trailing 12 Months

-89.8%

OGEN RSI Chart

OGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OGEN Valuation

Market Cap

3.7M

Price/Earnings (Trailing)

-0.34

Price/Sales (Trailing)

123.99

EV/EBITDA

0.66

Price/Free Cashflow

-0.44

OGEN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

OGEN Fundamentals

OGEN Revenue

Revenue (TTM)

37.7K

OGEN Earnings

Earnings (TTM)

-10.9M

Earnings Growth (Yr)

-24.51%

Earnings Growth (Qtr)

-34.97%

OGEN Profitability

EBT Margin

-27445.56%

Return on Equity

-110.92%

Return on Assets

-85.83%

Free Cashflow Yield

-226.93%

OGEN Investor Care

Shares Dilution (1Y)

923.91%

Diluted EPS (TTM)

17.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023133.5K116.2K37.7K37.7K
202298.1K109.3K120.4K131.5K
202100087.0K
2020827.5K580.7K333.8K0
20161.1M000
20151.1M1.0M1.2M1.2M
20141.1M1.2M1.2M939.9K
20131.1M1.0M1.0M1.0M
20121.5M1.4M1.3M1.3M
20111.3M1.4M1.4M1.4M
20100001.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About Oragenics Inc

OGEN
Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
 CEO
 WEBSITEoragenics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES6

Oragenics Inc Frequently Asked Questions

OGEN is the stock ticker symbol of Oragenics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Oragenics Inc is 3.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, OGEN's PE ratio (Price to Earnings) is -0.34 and Price to Sales (PS) ratio is 123.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OGEN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Oragenics Inc has provided -0.627 (multiply by 100 for percentage) rate of return.